The Relationship Of Brca Genetic Mutations With Family History Of Malignancy And Survival Rate In Epithelial Ovarian Carcinoma
Keywords:
Ovarian carcinoma, BRCA mutation, family history, survival rate, quality of lifeAbstract
Background: Epithelial ovarian carcinoma is one of the gynecological malignancies with high mortality. BRCA genetic mutations have been identified as important risk factors, but their association with family history and survival rate still requires further investigation.
Methods: This observational analytical study with a retrospective cohort design involved 62 patients with epithelial ovarian carcinoma. Data were collected through medical records, interviews, and paraffin block sample analysis. Statistical analysis included the Chi-square test and Kaplan-Meier survival analysis.
Results: The prevalence of BRCA mutations in patients with epithelial ovarian carcinoma was 50%, with 90.3% having BRCA1 mutations and 9.7% having BRCA2 mutations. There was a significant association between BRCA mutations and family history of malignancy (p = 0.020), with 58.1% of BRCA positive patients having a positive family history compared to 12.9% of BRCA negative patients having a positive family history. BRCA status was significantly correlated with the final status of the patient (p = 0.038), where the BRCA positive group showed a higher survival rate (67.7%) than the BRCA negative group (64.5%). Kaplan-Meier survival analysis for Overall Survival (OS) showed that patients with positive BRCA mutations had a median survival time of 20.87 months (SE 1.10), slightly higher than the BRCA negative group with a median of 19.03 months (SE 1.32). Although there was a difference of about 1.84 months, this result did not show statistical significance (p = 0.64). As for Progression Free Survival (PFS), patients with BRCA positive had a median time of 22.72 months (SE 0.73) compared to 21.67 months (SE 1.14) in the BRCA negative group. This difference of 1.05 months also did not show statistical significance (p = 0.48).
Conclusion: BRCA genetic mutations have a high prevalence in patients with epithelial ovarian carcinoma and are significantly associated with a history of malignancy in the family, chemotherapy administration, and the final status of the patient. Survival analysis using the Kaplan-Meier method for Overall Survival (OS) and Progression Free Survival (PFS) for 2 years did not show significant results.
Downloads
Metrics
References
American Cancer Society. (2022). Cancer Facts & Figures 2022 . Retrieved from www.cancer.org
Bolton, K.L., Chenevix-Trench, G., Goh, C., Sadetzki, S., Ramus, S.J., & Karlan, BY (2012). "Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer." JAMA , 307 (4), 382–390. https://doi.org/10.1001/jama.2012.20
Casaubon, J. T., Smith, A. R., & Lee, J. K. (2022). "Genetic predisposition and hereditary breast and ovarian cancer." Journal of Clinical Oncology , 40 (3), 215–230.
Centers for Disease Control and Prevention (CDC). (2021). "BRCA Mutations and Cancer Risk." Retrieved from www.cdc.gov
Euhus, D. M. (2022). "BRCA mutations and risk of breast and ovarian cancer." Cancer Journal , 28 (5), 290–305.
Green, A.C., Gago-Dominguez, M., & Matulonis, U.A. (2022). "Silent killer: The challenge of early detection in ovarian cancer." Nature Reviews Cancer , 22 (1), 15–30.
Ministry of Health of the Republic of Indonesia. (2018). Basic Health Research (Riskesdas) 2018. Retrieved from www.depkes.go.id
Mai, P.L., Friedman, S.C., & Narod, S.A. (2014). "Risks associated with BRCA1 and BRCA2 mutations." Journal of the National Cancer Institute , 106 (4), 1–18.
Modugno, F., & Edwards, R. P. (2013). "Ovarian cancer: Risk factors and prevention strategies." American Journal of Obstetrics & Gynecology , 209 (1), 77–86.
Page, C. M., Clendenning, M., & Goode, E. L. (2019). "BRCA mutations and survival outcomes in ovarian cancer patients." British Journal of Cancer , 120 (4), 382–390. https://doi.org/10.1038/s41416-019-0373-3
Petrucelli, N., Daly, M.B., & Feldman, G.L. (nd). "Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2." GeneReviews . Retrieved from www.ncbi.nlm.nih.gov
Reid, B. M., Permuth, J. B., & Sellers, T. A. (2017). "Ovarian cancer: Epidemiology, risk factors, and screening." Clinical Obstetrics and Gynecology , 60 (4), 687–707.
Siegel, R.L., Miller, K.D., & Jemal, A. (2020). "Cancer statistics, 2020." CA: A Cancer Journal for Clinicians , 70 (1), 7–30. https://doi.org/10.3322/caac.21590
Susan G. Komen Foundation. (2022). "BRCA Mutations and Cancer Risk." Retrieved from www.komen.org
WHO. (2020). Global Cancer Observatory: Cancer Today . Retrieved from www.who.int
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
